Angioedemas, Hereditary: all 173 studies

Page 1 of 2. Open to participants first (25), then studies with results posted, then the rest; newest registration first within each.

• EAP for Deucrictibant Immediate-releaseAvailableNCT07759141
• Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)RecruitingNCT07654829Phase 4
• Real-life Ecological Momentary Assessment of Lived Burden in Hereditary AngioEdemaRecruitingNCT07448181
• A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South KoreaRecruitingNCT07445087
• Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)RecruitingNCT07428499Phase 3
• Donidalorsen Treatment in Children With Hereditary AngioedemaRecruitingNCT07298447Phase 3
• A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary AngioedemaRecruitingNCT07293364Not applicable
• Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor DeficiencyRecruitingNCT07266805Phase 3
• A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in the Kingdom of Saudi ArabiaRecruitingNCT07263685
• A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in EgyptNot yet recruitingNCT07218393
• Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With SebetralstatAvailableNCT07216378
• A Long-Term Study of Navenibart in Participants With Hereditary AngioedemaEnrolling by invitationNCT07204938Phase 3
• Post Study Access of CSL312 (Garadacimab) for Pediatric Participants With Hereditary Angioedema Who Have Completed the CSL312_3003 StudyAvailableNCT07159464
• Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema PatientsRecruitingNCT07046806Phase 1/2
• A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)RecruitingNCT07001280
• STOP-HAE: A Phase 3 Study of ADX-324 in HAERecruitingNCT06960213Phase 3
• Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)RecruitingNCT06919003Phase 2
• Suicide Ideation in Hereditary AngioedemaNot yet recruitingNCT06811467
• Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAEEnrolling by invitationNCT06679881Phase 3
• Institutional Registry of Rare DiseasesRecruitingNCT06573723
• Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002Enrolling by invitationNCT06262399
• Angioedema Biomarker Research StudyRecruitingNCT06210698
• Identification and Characterization of Genetic Variants in Hereditary AngioedemaNot yet recruitingNCT05833620
• Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary AngioedemaEnrolling by invitationNCT05396105Phase 2/3
• Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat StudiesEnrolling by invitationNCT04933721Phase 3
• Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or IICompletedNCT06467084Phase 3Results posted
• CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary AngioedemaCompletedNCT05819775Phase 3Results posted
• A Study of Navenibart (STAR-0215) in Participants With Hereditary AngioedemaCompletedNCT05695248Phase 1/2Results posted
• A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)CompletedNCT05460325Phase 3Results posted
• Berotralstat Treatment in Children With Hereditary AngioedemaActive, not recruitingNCT05453968Phase 3Results posted
• A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)CompletedNCT05259917Phase 3Results posted
• OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)CompletedNCT05139810Phase 3Results posted
• Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type IITerminatedNCT05047185Phase 2Results posted
• Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema AttacksCompletedNCT04739059Phase 3Results posted
• Expanded Access Program With Lanadelumab for Japanese People With Hereditary AngioedemaCompletedNCT04687137Phase 3Results posted
• CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema AttacksCompletedNCT04656418Phase 3Results posted
• A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary AngioedemaCompletedNCT04654351Phase 3Results posted
• Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary AngioedemaCompletedNCT04618211Phase 2Results posted
• A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-InhibitorCompletedNCT04444895Phase 3Results posted
• An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary AngioedemaCompletedNCT04307381Phase 2Results posted
• A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or IICompletedNCT04208412Phase 2Results posted
• A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)CompletedNCT04206605Phase 3Results posted
• Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)CompletedNCT04180163Phase 3Results posted
• A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in ChildrenCompletedNCT04070326Phase 3Results posted
• FIRAZYR General Drug Use-Results Survey (Japan)CompletedNCT04057131Results posted
• A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary AngioedemaCompletedNCT04030598Phase 2Results posted
• A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese ParticipantsCompletedNCT03888755Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in JapanCompletedNCT03873116Phase 3Results posted
• A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)CompletedNCT03712228Phase 2Results posted
• Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAECompletedNCT03485911Phase 3Results posted
• A Long Term Safety Study of BCX7353 in Hereditary AngioedemaCompletedNCT03472040Phase 2/3Results posted
• Study of BCX7353 as a Treatment for Attacks of Hereditary AngioedemaCompletedNCT03240133Phase 2Results posted
• Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary AngioedemaCompletedNCT02870972Phase 2Results posted
• Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)CompletedNCT02865720Phase 3Results posted
• Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAECompletedNCT02741596Phase 3Results posted
• Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult SubjectsCompletedNCT02663687Phase 1Results posted
• Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAECompletedNCT02586805Phase 3Results posted
• Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary AngioedemaCompletedNCT02584959Phase 3Results posted
• A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary AngioedemaCompletedNCT02316353Phase 3Results posted
• 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE AttacksCompletedNCT02303626Phase 2/3Results posted
• A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 InhibitorCompletedNCT02247739Phase 2Results posted
• A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema ParticipantsCompletedNCT02093923Phase 1Results posted
• Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary AngioedemaCompletedNCT02052141Phase 3Results posted
• Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese VolunteersCompletedNCT02045264Phase 1Results posted
• A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary AngioedemaCompletedNCT01912456Phase 3Results posted
• Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema AttacksCompletedNCT01756157Phase 2Results posted
• A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous RouteCompletedNCT01576523Phase 1/2Results posted
• Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAECompletedNCT01457430Phase 4Results posted
• A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human HyaluronidaseCompletedNCT01426763Phase 2Results posted
• A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary AngioedemaCompletedNCT01386658Phase 3Results posted
• Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) PatientsCompletedNCT01359969Phase 2Results posted
• Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE AttacksCompletedNCT01188564Phase 3Results posted
• Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent RejectionCompletedNCT01134510Phase 1/2Results posted
• CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12CompletedNCT01095510Phase 2Results posted
• A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE AdministrationCompletedNCT01095497Phase 2Results posted
• Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary AngioedemaCompletedNCT01059526Results posted
• C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) AttacksCompletedNCT01005888Phase 3Results posted
• EASSI - Evaluation of the Safety of Self-Administration With IcatibantCompletedNCT00997204Phase 3Results posted
• A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZECompletedNCT00914966Phase 4Results posted
• A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)CompletedNCT00912093Phase 3Results posted
• A Study of the Safety and Immunogenicity of Repeated rhC1INH AdministrationCompletedNCT00851409Phase 2Results posted
• Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)CompletedNCT00500656Phase 3Results posted
• Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) AttacksCompletedNCT00462709Phase 3Results posted
• Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)CompletedNCT00457015Phase 3Results posted
• Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)CompletedNCT00456508Phase 3Results posted
• Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) AttacksCompletedNCT00438815Phase 3Results posted
• C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)CompletedNCT00292981Phase 3Results posted
• C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) AttacksCompletedNCT00289211Phase 3Results posted
• Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedNCT00262301Phase 3Results posted
• Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)CompletedNCT00262080Phase 3Results posted
• Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedNCT00225147Phase 2/3Results posted
• Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) AttacksCompletedNCT00168103Phase 2/3Results posted
• Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary AngioedemaCompletedNCT00097695Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced AngioedemaCompletedNCT07290855Phase 4
• A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple CountriesCompletedNCT07251933
• A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE AttacksCompletedNCT07009262
• A Phase 2 in Adult Subjects With Hereditary AngioedemaActive, not recruitingNCT06846398Phase 2
• A Study of Navenibart in Participants With Hereditary AngioedemaActive, not recruitingNCT06842823Phase 3
• Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to GaradacimabCompletedNCT06806657Phase 4
• HAE Burden and Crisis ManagementCompletedNCT06806618

← Angioedemas, Hereditary overview